LBA and Hybrid LCMS Quantitation of Biotherapeutics and Biomarkers, Upcoming Webinar Hosted by Xtalks
In this free webinar, the featured speakers will compare LBA vs Hybrid LCMS and explain how to choose which approach to use. They will look at case studies highlighting the advantage of each technology and case studies where an alternate technology was necessary.
TORONTO, June 22, 2020 /PRNewswire-PRWeb/ -- The field of quantitation of large molecules or proteins has been around for a long time. Typically, ligand binding assays (LBA) have dominated this area. However, the use of mass spectrometry in this field has gained a lot of momentum in the last several years.
This now necessitates the question "How do you choose which approach to use (LBA or MS)?" In many cases, either technology can answer the question, but there are definitely times when one technology has advantages over the other. There are several questions which might lead to specific direction, such as "what type of reagents are available?" or "do you need to differentiate a small amino acid change?"
This webinar will give an overview of each approach and discuss the types of questions that will help guide one to choose the correct technology. For the LBA, we will discuss the different types of ligand binding assays, answers to common questions that can lead to performing LBA vs. hybrid LCMS and some advantages of LBA over LCMS methodologies.
For Hybrid LCMS, we will discuss and highlight various approaches for using immunoaffinity LCMS or hybrid LCMS, from enrichment at the protein level to enrichment at the peptide level, using either bead-based or column-based enrichment strategies.
The presenters will also give examples and case studies of where each technology was applied successfully and where they had to pivot to an alternate technology.
Join Franklin Spriggs, MS Director, Biopharmaceutical LBA Services, KCAS Bioanalytical and Biomarker Services and Dawn Dufield, PhD, Director, Biopharmaceutical LC-MS/MS Services, KCAS Bioanalytical and Biomarker Services in a live webinar on Friday, July 10, 2020 at 12pm EDT (5pm BST/UK).
For more information or to register for this event, visit LBA and Hybrid LCMS Quantitation of Biotherapeutics and Biomarkers.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
SOURCE Xtalks
Share this article